This new agreement formalizes the relationship that PharmaCore has developed with PharmaAdvance since its inception in 2006. The alliance enables PharmaCore to jointly work on projects with PharmaAdvance to take advantage of the lower cost structure of Chinese providers and pass these savings along to their customers. The new partnership will allow PharmaCore customers to utilize PharmaAdvance’s synthetic expertise in conjunction with US-based project management and leadership.

“PharmaAdvance has a proven track record of reliability and technical competence, and this new partnership allows us to utilize their services as a flexible extension of PharmaCore’s FTE and custom synthesis capabilities,” said Rob Maddox, president of PharmaCore. “This alliance will provide PharmaCore’s customers with an avenue to realize significant cost savings by having their projects carried out in China while being managed by PharmaCore personnel. Our customers will receive the same customer service that PharmaCore is known for, and will not observe any compromise in quality of work on their projects or delivery time lines.”

“PharmaCore is one of our earliest and most important collaborators. We are very pleased that the two companies are formalizing the alliance after a successful and productive four-year collaboration. Formalization of the alliance is a testament to the quality and the capability of PharmaAdvance’s services”, said Don (Xiaodong) Wang, chairman and CEO of PharmaAdvance. “By combining the strong chemistry expertise and capability of the two companies, cost saving advantages found in China, as well as the excellent leadership of PharmaCore in the industry, this alliance will enable PharmaCore’s clients to enjoy the same quality of chemistry services found in the US while benefiting from the lower cost in China.”